Literature DB >> 1793521

Drug-induced orthostatic hypotension.

J A Schoenberger1.   

Abstract

Drug-induced orthostatic hypotension is an important clinical problem. When symptomatic, it is poorly tolerated by the patient, and can be a cause for discontinuing treatment. It may have more serious consequences if it leads to syncope, falls and injury, or to sustained loss of perfusion of vital organs resulting in heart attack or stroke. Orthostatic hypotension is easily detected by procedures available to all physicians, who should maintain a high index of suspicion when prescribing drugs commonly known to cause this condition, especially in the elderly. Since the medical conditions calling for the use of these drugs are extremely prevalent, the screening and monitoring of orthostatic hypotension should be instituted as a routine precaution in appropriate patients. Hypertension affects two-thirds of elderly patients. Orthostatic hypotension is an infrequent adverse effect of most of the drugs in current use in the treatment of hypertension; it is, however, more common with alpha 1-blockers (first dose), adrenergic blockers and centrally acting drugs. Sudden loss of blood volume, or excess diuresis, may precipitate orthostatic hypotension in any hypertensive patient. Drugs used for the treatment of psychiatric illnesses are all associated with a significant incidence of orthostatic hypotension: phenothiazines, tricyclic antidepressants and monoamine oxidase inhibitors. Cardiovascular drugs associated with hypotension include dopamine agonists, antianginals and antiarrhythmics.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1793521     DOI: 10.2165/00002018-199106060-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  7 in total

Review 1.  Orthostatic hypotension.

Authors:  S L Mader
Journal:  Med Clin North Am       Date:  1989-11       Impact factor: 5.456

Review 2.  Aging and postural hypotension. An update.

Authors:  S L Mader
Journal:  J Am Geriatr Soc       Date:  1989-02       Impact factor: 5.562

3.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1988-05

4.  Race and sex differentials in the impact of hypertension in the United States. The National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study.

Authors:  J Cornoni-Huntley; A Z LaCroix; R J Havlik
Journal:  Arch Intern Med       Date:  1989-04

Review 5.  Beta-adrenergic blockers.

Authors:  W H Frishman
Journal:  Med Clin North Am       Date:  1988-01       Impact factor: 5.456

6.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

Review 7.  Drug treatment as a cause of falls in old age. A review of the offending agents.

Authors:  A J Campbell
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

  7 in total
  10 in total

1.  Autonomic Nervous System Dysfunction in Parkinson's Disease.

Authors:  Theresa A. Zesiewicz; Matthew J. Baker; Mervat Wahba; Robert A. Hauser
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

Review 2.  Postural blood pressure changes and orthostatic hypotension in the elderly patient: impact of antihypertensive medications.

Authors:  Ihab Hajjar
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Drug-induced orthostatic hypotension in the elderly: avoiding its onset.

Authors:  I Verhaeverbeke; T Mets
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

4.  Baseline depressive symptoms are not associated with clinically important levels of incident hypertension during two years of follow-up: the multi-ethnic study of atherosclerosis.

Authors:  Joseph A C Delaney; Bruce E Oddson; Holly Kramer; Steven Shea; Bruce M Psaty; Robyn L McClelland
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

Review 5.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

Review 6.  Parkinson disease and comorbid cerebrovascular disease.

Authors:  Wandana Nanhoe-Mahabier; Karlijn F de Laat; Jasper E Visser; Jan Zijlmans; Frank-Erik de Leeuw; Bastiaan R Bloem
Journal:  Nat Rev Neurol       Date:  2009-09-01       Impact factor: 42.937

7.  Orthostatic hypotension in drug-naïve patients with Parkinson's disease.

Authors:  Hyo-Jin Bae; Sang-Myung Cheon; Jae Woo Kim
Journal:  J Mov Disord       Date:  2011-04-30

8.  Metopimazine is primarily metabolized by a liver amidase in humans.

Authors:  Robert W Busby; Xiaokun Cai; Sihyung Yang; Luis Ramos; Lata Venkatarangan; Helen Shen; Stephen Wax; Abu J M Sadeque; Cyril De Colle
Journal:  Pharmacol Res Perspect       Date:  2022-02

9.  Orthostatic Hypotension and Antiparkinsonian Drugs: A Systematic Review and Meta-analysis.

Authors:  Danielle Nimmons; Cini Bhanu; Mine Orlu; Anette Schrag; Kate Walters
Journal:  J Geriatr Psychiatry Neurol       Date:  2021-12-29       Impact factor: 2.718

10.  Systolic orthostatic hypotension is related to lowered cognitive function: Findings from the Maine-Syracuse Longitudinal Study.

Authors:  Rachael V Torres; Merrill F Elias; Georgina E Crichton; Gregory A Dore; Adam Davey
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-09-19       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.